Navigation Links
ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents

SAN DIEGO, July 21, 2014 /PRNewswire/ -- An International Trade Commission (ITC) ruling issued Friday held that, despite a redesign of its iCH CPAP device, Taiwanese device manufacturer APEX continues to infringe ResMed patents in its humidification. ResMed (NYSE: RMD) is the innovation leader and pioneer in designing and manufacturing devices for the treatment of sleep-disordered breathing.

"Our research and development teams are constantly researching and improving designs to reach new levels of comfort, performance and efficacy," said David Pendarvis, ResMed chief administrative officer and global general counsel. "This result – and APEX's own expert – affirms that the superior quality and functionality generated by ResMed innovation cannot be duplicated."

The original ITC action filed by ResMed in March 2013 asserted patent infringement by four products: APEX iCH and XT Fit CPAP humidifiers, the WiZARD 220 full face mask, and the WiZARD 210 nasal mask.
In July 2013, APEX agreed to entry of an order prohibiting it from infringing ResMed's patents.  And as a result, APEX has been banned from selling infringing products in the United States. 

APEX then redesigned its products and sought a ruling that it had avoided ResMed's patents. In this new ruling, the full commission held that the APEX iCH humidifier continues to infringe.  As a result, APEX should continue to be banned from selling the iCH humidifier in the United States. The redesigned APEX XT Fit was found not to infringe. But APEX's own expert stated that the redesigned humidifiers compromised on functionality and performance.  The redesigned WiZARD 220 full face mask – which now has a fused elbow instead of the more desirable detachable elbow -- was found not to infringe on ResMed patents.  Again, APEX's expert noted that the redesigned masks sacrificed functional advantages present in the ResMed products.  Finally, APEX chose to withdraw its redesigned WiZARD 210 nasal mask from these proceedings, so the July 2013 order remains in place as to that product.

About ResMed:
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit For News Media For InvestorsGretchen Griswold

Agnes LeeDirector, Global Corporate Communications

Senior Director, Investor RelationsO: 858-836-6789


investorrelations@resmed.comLogo -

SOURCE ResMed Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
2. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
3. Announcement Under Irish Takeover Rules Relevant Securities in Issue
4. 2013 Chinese Pharmaceutical Guidebook: Drug Registration Rules
5. Arizona Judge Rules That Arizona Medical Marijuana Law is Constitutional
6. EMD Seronos Redesigned Fertility Pen Available for Distribution in US
7. Upsher-Smith Introduces Newly Redesigned Corporate Website
8. Vicks Starry Night Humidifier Available Now in New Colors Exclusively at Babies"R"Us
9. Newly Published Survey Shows Drug Shortages Still Have Major Impact on Patient Care
10. Despite A Difficult Competitive Environment, Opportunities Can Still Be Found In The Growing US Trauma Fixation Device Market
11. Yaz Settlement Funding News: 10K Cases Still Not Settled
Post Your Comments:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):